| Assessment Status | Rapid Review Complete |
| HTA ID | 24046 |
| Drug | Tenecteplase |
| Brand | Metalyse® |
| Indication | Tenecteplase (Metalyse®) is indicated in adults for the thrombolytic treatment of acute ischaemic stroke (AIS) within 4.5 hours from last known well and after exclusion of intracranial haemorrhage. |
| Assessment Process | |
| Rapid review commissioned | 08/11/2024 |
| Rapid review completed | 27/11/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that tenecteplase be considered for reimbursement*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.